Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Liabilities (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Total Liabilities data on record, last reported at $5.1 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 7.22% year-over-year to $5.1 million; the TTM value through Sep 2025 reached $5.1 million, down 7.22%, while the annual FY2024 figure was $4.8 million, 20.67% down from the prior year.
  • Total Liabilities reached $5.1 million in Q3 2025 per GANX's latest filing, down from $6.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $7.4 million in Q2 2024 and bottomed at $3.6 million in Q1 2021.
  • Average Total Liabilities over 5 years is $5.5 million, with a median of $5.7 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: skyrocketed 5181.04% in 2021, then dropped 20.67% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $4.2 million in 2021, then grew by 25.25% to $5.2 million in 2022, then increased by 15.54% to $6.0 million in 2023, then decreased by 20.67% to $4.8 million in 2024, then rose by 5.81% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $5.1 million in Q3 2025, $6.1 million in Q2 2025, and $5.8 million in Q1 2025.